Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 Marleen Kok (@lab_kok) of @NKI_nl talks on multiplexed analysis and spatial histology to predict response to immunotherapy in breast cancer

Watch: 👉http://ow.ly/KGgk50NnI0B👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638229021719666697Retweet on Twitter 1638229021719666697Like on Twitter 16382290217196666972Twitter 1638229021719666697
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 | If you were interested in Enrico Franceschi’s (@AUSLBologna) talk on #medulloblastoma, watch our exclusive interview with him on overcoming resistance and the need to preserve fertility in patients!

http://ow.ly/H4XS50NnJAf

@myESMO #btsm

Reply on Twitter 1638128900587790336Retweet on Twitter 1638128900587790336Like on Twitter 16381289005877903364Twitter 1638128900587790336
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 @evaciruelos of Hospital 12 de Octubre talks on unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Watch: 👉http://ow.ly/P2rn50NmZNc👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638114521540599809Retweet on Twitter 16381145215405998091Like on Twitter 16381145215405998092Twitter 1638114521540599809
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 continues, and we’ve already been speaking with experts about their research ⚗️🔬

Make sure to keep an eye out on http://VJOncology.com for key updates in the field of #rarediseases & #sarcoma!

@VJOncology @myESMO #scmsm

Reply on Twitter 1638088395002990596Retweet on Twitter 16380883950029905961Like on Twitter 1638088395002990596Twitter 1638088395002990596
VJOncologyVJ Oncology@VJOncology·
March 20, 2023

🎥 @stolaney1 of @DanaFarberNews talks on conducting clinical trials in countries that are unlikely to be able to afford innovative drugs

Watch: 👉http://ow.ly/Cr4g50NmZpj👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1637871667958390806Retweet on Twitter 16378716679583908064Like on Twitter 163787166795839080611Twitter 1637871667958390806
Load More

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 Marleen Kok (@lab_kok) of @NKI_nl talks on multiplexed analysis and spatial histology to predict response to immunotherapy in breast cancer

Watch: 👉http://ow.ly/KGgk50NnI0B👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638229021719666697Retweet on Twitter 1638229021719666697Like on Twitter 16382290217196666972Twitter 1638229021719666697
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 | If you were interested in Enrico Franceschi’s (@AUSLBologna) talk on #medulloblastoma, watch our exclusive interview with him on overcoming resistance and the need to preserve fertility in patients!

http://ow.ly/H4XS50NnJAf

@myESMO #btsm

Reply on Twitter 1638128900587790336Retweet on Twitter 1638128900587790336Like on Twitter 16381289005877903364Twitter 1638128900587790336
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 @evaciruelos of Hospital 12 de Octubre talks on unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Watch: 👉http://ow.ly/P2rn50NmZNc👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638114521540599809Retweet on Twitter 16381145215405998091Like on Twitter 16381145215405998092Twitter 1638114521540599809
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 continues, and we’ve already been speaking with experts about their research ⚗️🔬

Make sure to keep an eye out on http://VJOncology.com for key updates in the field of #rarediseases & #sarcoma!

@VJOncology @myESMO #scmsm

Reply on Twitter 1638088395002990596Retweet on Twitter 16380883950029905961Like on Twitter 1638088395002990596Twitter 1638088395002990596
VJOncologyVJ Oncology@VJOncology·
March 20, 2023

🎥 @stolaney1 of @DanaFarberNews talks on conducting clinical trials in countries that are unlikely to be able to afford innovative drugs

Watch: 👉http://ow.ly/Cr4g50NmZpj👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1637871667958390806Retweet on Twitter 16378716679583908064Like on Twitter 163787166795839080611Twitter 1637871667958390806
Load More

Watch all videos from ASCO GU 2023!

View all videos
2:20
Key survivorship challenges following surgery for bladder cancer
Siamak Daneshmand • 16 Feb 2023
2:39
Does every patient with localized muscle-invasive bladder cancer need a cystectomy?
Siamak Daneshmand • 16 Feb 2023
0:38
Targetable alterations in bladder cancer
Siamak Daneshmand • 16 Feb 2023
2:59
TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPC
Alan Haruo Bryce • 16 Feb 2023

Bladder Cancer at ASCO GU 2023!

View all
2:39
Does every patient with localized muscle-invasive bladder cancer need a cystectomy?
Siamak Daneshmand • 16 Feb 2023
0:38
Targetable alterations in bladder cancer
Siamak Daneshmand • 16 Feb 2023
2:20
Key survivorship challenges following surgery for bladder cancer
Siamak Daneshmand • 16 Feb 2023
0:47
What to look forward to in urothelial cancer at ASCO GU 2023
Arlene Siefker-Radtke • 16 Feb 2023

Prostate Cancer at ASCO GU 2023!

View all
2:59
TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPC
Alan Haruo Bryce • 16 Feb 2023
1:33
Guidelines for using PSMA PET in the staging of prostate cancer
David M. Nanus • 16 Feb 2023
4:12
Active surveillance in localized prostate cancer
Anthony Victor D'Amico • 16 Feb 2023
0:50
CheckMate 650: nivolumab + ipilimumab, ipilimumab alone, or cabazitaxel in mCRPC
Russell Kent Pachynski • 18 Feb 2023

Kidney Cancer at ASCO GU 2023!

View all
0:53
CARINA: cabozantinib post first-line immune-oncology CPI-containing combination in aRCC
Anand Sharma • 16 Feb 2023
0:35
The latest developments in adjuvant therapy for RCC
Matthew R. Zibelman • 16 Feb 2023
1:02
Post-second-line systemic treatment for advanced RCC
Tian Zhang • 17 Feb 2023
6:16
Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
Michael Atkins • 17 Feb 2023
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals